Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
- Status
- TERMINATED
- Phase
- PHASE3
Clinical Trials Related to Blinatumomab
Related studies linked through entity extraction aliases.
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
- Status
- COMPLETED
- Phase
- PHASE2
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)
- Status
- COMPLETED
- Phase
- PHASE2
Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
- Status
- COMPLETED
- Phase
- PHASE2